B7-1 CD80-TRANSDUCED TUMOR-CELLS ELICIT BETTER SYSTEMIC IMMUNITY THANWILD-TYPE TUMOR-CELLS ADMIXED WITH CORYNEBACTERIUM-PARVUM

Citation
Lp. Chen et al., B7-1 CD80-TRANSDUCED TUMOR-CELLS ELICIT BETTER SYSTEMIC IMMUNITY THANWILD-TYPE TUMOR-CELLS ADMIXED WITH CORYNEBACTERIUM-PARVUM, Cancer research, 54(20), 1994, pp. 5420-5423
Citations number
16
Categorie Soggetti
Oncology
Journal title
ISSN journal
00085472
Volume
54
Issue
20
Year of publication
1994
Pages
5420 - 5423
Database
ISI
SICI code
0008-5472(1994)54:20<5420:BCTEBS>2.0.ZU;2-M
Abstract
Tumor cells genetically modified by transduction of B7 (B7-1/CD80), a natural ligand for the T-cell costimulatory molecules CD28 and CTLA-4, can elicit potent tumor immunity, and they can be effective for treat ment of established cancers in animal models. In this study, three tum or lines, the EL4 lymphoma, the P815 mastocytoma, and the MCA102 sarco ma mere transduced with recombinant retrovirus containing the murine B 7 gene, and their potency to induce systemic immunity protective again st challenge with wild-type tumor nas compared to that of the same tum or cells admired with the commonly used adjuvant Corynebacterium parvu m. While admixture of tumor cells with C. parvum resulted in complete regression of tumors in syngeneic mice, it did not induce protective i mmunity against a subsequent challenge of mild-type cells from any of the 3 tumors tested. In contrast, B7-transduced EL4 and P815 tumors re gressed locally and induced a potent systemic immunity to wild-type tu mors and a higher level of cytotoxic T-cell activity than did tumor ce lls admixed with C. parvum. No systemic immunity was induced by B7-tra nsduced nonimmunogenic MCA102 sarcoma cells. Our results demonstrate t hat immunogenic tumor cells transduced with the B7 gene are superior t o tumor cells mixed with C. parvum for the induction of systemic tumor immunity.